Merck & Co announced yesterday that it is aiming for the approval of two cardiovascular drugs in the United States and the European Union for 2013. The two drugs are vorapaxar, an experimental drug for acute coronary syndrome chest pain caused by coronary artery disease, and K-524A (tredaptive), for the treatment of HDL (bad cholesterol) to reduce the incidence of vascular events. The company made the announcement at the European Society for Cardiology 2012 Congress, in Munich, Germany.
